- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Treatment of Pediatric Malignant Tumors with VP‐16
Search this article
Description
<jats:title>Abstract</jats:title><jats:p>The West Japan Pediatric Oncology Group studied the treatment of pediatric malignant tumors with VP‐16 from December 1984 to March 1988. Study subjects were divided into two groups. One group received only VP‐16, while the other received VP‐16 combined with other anti‐tumor agents. VP‐16 evaluation was possible in a total of 116 cases. The efficacy rate was calculated by considering both complete and partial remission as effective. The efficacy rate for VP‐16 alone was 87.5% for primary cases of ANLL and 100% for primary cases of histiocytosis. The efficacy rates for combination therapy were as follows: 92.6% for primary cases of ANLL, 66.7% for primary cases of histiocytosis, 45.5% for relapsed cases of ANLL and 66.7% for relapsed cases of ALL. Bone marrow suppression was seen in the form of leukopenia and thrombocytopenia for 2 to 3 weeks after VP‐16 administration. Alopecia, mucositis and gastrointestinal symptoms were also observed, but they presented no significant problem. From our results, we believe that chemotherapy including VP‐16 is effective for remission induction therapy in primary cases of ANLL and for salvage therapy in relapsed leukemia. Additionally, VP‐16 is considered to be effective for the treatment of histiocytosis.</jats:p>
Journal
-
- Pediatrics International
-
Pediatrics International 32 299-307, 1990-06-01
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1870583642558342656
-
- ISSN
- 1442200X
- 13288067
-
- Data Source
-
- OpenAIRE